The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Agree that it is good indicator that DG has taken a consultant role re 002 liaison with far east licensee. He knows the score there and will be straight up to speed.
Be nice to have some news very soon, hopefully there is a lot going on behind the scene on 002 durability, new CEO and 004 patents/ contact with originator, as alluded to by AR.
GLA
As often happens for NFX many buys are showing as sells, so the sea of red trades is very misleading.
About 2.97 million buys today compared to 2.5 miilion sells today.
All trades of 0.8949 and above were buys.
Most of the larger trades this pm (gone through at around 0.90p) that are shown as sells are in fact buys. (50,000/ 665,453/ 99,967/ 100,057 and 500,000 trades by volume).
This war will accelerate the need and desire for other ways to produce food and wean ourselves off artificial fertiliser which requires potash and other minerals from Russia plus need lots and lots of Russian gas to make.
This share should really be going up to reflect future potential.
I am intrigued by some peoples comments on here. It is as if they live in a bubble and do not know that Putin's attacking Ukraine or just think its irrelevant to their investments! It affects all investments in some way - with most being badly affected - today 68% of shares were down, 23% were unchanged and 9% were up, and it has been the same most of this week.
Whilst one part of me wants positive news to be RNS'd the other rational side knows that there is little point to releasing good news under these conditions. So whatever significant news Riddell was alluding to will hopefully wait till things are a little more stable.
Hopefully Ukraine will be resolved as peacefully, quickly and with as few further casualties as possible.
Have a good weekend all.
Closing phrase from the auditors official resigning note states following:
"We consider that none of the reasons for us ceasing to hold office and no matters connected with us ceasing to hold office need to be brought to the attention of members of creditor of the company".
So nothing to worry about – just usual auditor merry go round.
NFX was third from top of ADVFN risers board earlier this afternoon and now at the very top of ADVFN risers board.
Good to see some positive action for a change.
Agree with questions re NXP001 for CINV. Thought Oxilio had oncology use and Nuformix still had rights to CINV.
Needs clarifying.
Morning ForFXSake
Being pedantic this was not an issue of grammar but one of spelling (or typing).
Ho hum.
Hi Littlened, out of genuine interest, do you have examples of companies where a change of advisor was the prelude (introduction/ start) to bid action?
Thanks
Or did they mean to type 'Advisor change often preludes bid action'?
Nuformix has granted a total of 3,000,000 warrants each to Dr Alastair Riddell, Dr Julian Gilbert and Maddy Kennedy with an exercise price of 1.45p per share.
I believe it means that when either AR, JG or MK exercise their warrants they have to pay 1.45p per share for the privilege.
Realistically that means that AR, JG or MK will only exercise their warrants at a price well above 1.45p per share and make gains as per below.
Price exercised and Gain made below
1.45p = Zero gain
2.90p = £43,500 gain
4.35p = £87,000 gain
5.80p = £130,500 gain
7.15p = £174,000 gain
8.60p = £217,500 gain
For once I agree with your comments goupplease.
A classic case of 'the lady doth protest too much' - clogging up the board with his insecurity.
Anyway.
I have just caught up with the (useful) posts since I last looked-in in December.
Well done Soupdragon for maintaining some semblance of control here by reminding people of the facts and debunking the frequent fictions being touted.
Also hi to our resident Waldo and Statler for your alternative views on things.
Hopefully things moving in the right direction from here.
GLA
I understand the pessimism FFS.
But for the sake of a happy new year weekend I am hanging my hat, and everything else on these very recent comments to shareholders by Riddell.
• The Board is confident, following recent preclinical data in NXP002 and the strengthening of its IP portfolio around NXP004, that the near-term prospects for these products are strong
• (Those prospects) will be further enhanced by additional pre-clinical development, including formulation work, toxicology studies, and preparations for Phase I trials, in addition to parallel business development work with potential partners.
• As the business strategy is executed, the Company is confident that this will be reflected by an increase in the share price, which will both increase the amount of money received by Nuformix in the Lanstead subscription, but also benefit Lanstead as the value of its investment will be higher.
This price seems slightly crazy. Can only hope the new year is a lot lot better.
Wishing you and all demoralised Nuformix shareholders a Happy New Year.
GLA
Someone has done a B&B transfer into their ISA for the full £20k allowance.
God timing as get max number in isa
Not unusual for buys to be shown as sells.
Just means that you bought them at a slightly better price than the mid-point of the advertised bid/ ask implies.
Shows that IMM have been pleased with the previous Lanstead subscriptions in earlier years - otherswise they would not have used them again.
However glad our bod did not issue warrants with the subscription.
The fact that the company has agreed that Lanstead will only start selling down the tranche ! shares after 17th February 2022 for a first payment to Nuformix after March 2022 is intriguing.
Agree about the subscription happening now - why not wait 4 months until April next year when they could have done it in one hit rather in this split form? We seem to have just under £1m in cash at present so surely no rush?
The only reasons I can think is that (1) Lanstead were offering the 2p benchmark and that the bod strongly felt that they should accept Lanstead before imminent newsflow increased the sp and the benchmark figure with it and (2) they possibly wanted to get longterm funding in place to attract new CEO/ Business development director.
AR and AB are no fools (hopefully).
We have brilliant results for 004 and 002.
Now pursuing licensing deal for 004 to extend patent life and reduce side effects of a market leader £billion a year oncology drug, negotiations for which could be revealed in coming weeks/ months.
Will start to pursue licensing deal for 002 - a potential £billion a year drug for IPF.
We now hopefully have funds in place to get 002 pre-clinical phase completed.
New CEO and further positive results expected shortly.
The company is now in a very strong position, compared to 9 months ago, with massive potential on the horizon and yet the sp is on the floor.
I see a massive buy opportunity.
Tally ho
GLA